Deep Track Capital, LP
GREENWICH, CT
$6.8bn in 66 US stocks at the end of 30 June 2026. The top 10 are 40.1% of the money. It changed about 26.9% of the portfolio this quarter.
Value
$6.8bn
Stocks
66
Top 10 share
40.1%
Turnover
26.9%
What changed this quarter
New
Bought for the first time this quarter.
- Alnylam PharmaceuticalsALNY3.7% of the fund
- Hemab Therapeutics HoldingsCOAG1.9% of the fund
- GH ResearchGHRS1.3% of the fund
- United TherapeuticsUTHR1.0% of the fund
- Avalo TherapeuticsAVTX1.0% of the fund
- AltimmuneALT0.9% of the fund
- GeneDx HoldingsWGS0.7% of the fund
- HarrowHROW0.6% of the fund
- Immix BiopharmaIMMX0.4% of the fund
- Shattuck LabsSTTK0.4% of the fund
- MannkindMNKD0.4% of the fund
- Generate BiomedicinesGENB0.3% of the fund
- Nektar TherapeuticsNKTR0.3% of the fund
- Olema PharmaceuticalsOLMA0.3% of the fund
- Kailera TherapeuticsKLRA0.2% of the fund
- KardiganKARD0.2% of the fund
- Enliven TherapeuticsELVN0.2% of the fund
- XencorXNCR0.1% of the fund
Added
Bought more of a stock they already held.
- Structure TherapeuticsGPCR3.7% of the fund+11%
- VeradermicsMANE3.6% of the fund+300%
- Nuvalent3.2% of the fund+30%
- Alkermes plc.ALKS3.1% of the fund+11%
- Biomarin PharmaceuticalBMRN2.8% of the fund+188%
- Nurix TherapeuticsNRIX2.8% of the fund+22%
- Ionis PharmaceuticalsIONS2.6% of the fund+13%
- Genmab A/SGMAB2.3% of the fund+54%
- MoonLake ImmunotherapeuticsMLTX2.0% of the fund+9%
- Tango TherapeuticsTNGX1.9% of the fund+53%
- GrailGRAL1.8% of the fund+7%
- Maze TherapeuticsMAZE1.6% of the fund+7%
- Celldex TherapeuticsCLDX1.6% of the fund+129%
- Cogent BiosciencesCOGT1.1% of the fund+100%
- AtaiBeckleyATAI1.1% of the fund+20%
- Viridian TherapeuticsVRDN1.0% of the fund+158%
- PersonalisPSNL0.8% of the fund+33%
- Beam TherapeuticsBEAM0.5% of the fund+22%
Cut
Sold some of their stake.
- ImmunovantIMVT5.3% of the fund-19%
- Oruka TherapeuticsORKA2.7% of the fund-5%
- AlumisALMS2.6% of the fund-6%
- Vera TherapeuticsVERA2.5% of the fund-3%
- Axsome TherapeuticsAXSM2.5% of the fund-36%
- Definium TherapeuticsDFTX1.9% of the fund-8%
- MBX BiosciencesMBX1.4% of the fund-37%
- CytokineticsCYTK0.9% of the fund-49%
- Dyne TherapeuticsDYN0.5% of the fund-25%
- X4 PharmaceuticalsXFOR0.4% of the fund-7%
- Kura OncologyKURA0.3% of the fund-25%
- Enanta PharmaceuticalsENTA0.3% of the fund-26%
- Immunocore HldgsIMCR0.1% of the fund-84%
- InventivaIVA<0.1% of the fund-35%
Sold out
Sold their entire stake.
- Apellis Pharmaceuticals-100%
- Centessa Pharmaceuticals-100%
- BridgeBio PharmaBBIO-100%
- Terns Pharmaceuticals-100%
- GeronGERN-100%
- ANI PharmaceuticalsANIP-100%
- Soleno Therapeutics-100%
- Engene Holdings-100%
- Apogee TherapeuticsAPGE-100%
- Janux TherapeuticsJANX-100%
- Crescent BiopharmaCBIO-100%
- Larimar TherapeuticsLRMR-100%
- Helus PharmaHELP-100%
- BillionToOneBLLN-100%
Holdings
- Structure TherapeuticsGPCR
- Share
- 3.7%
- Value
- $254m
- Shares
- 4,740,072
+11%
- Nuvalent
- Share
- 3.2%
- Value
- $220m
- Shares
- 1,783,322
+30%
- Genmab A/SGMAB
- Share
- 2.3%
- Value
- $155m
- Shares
- 5,650,000
+54%
- Hemab Therapeutics HoldingsCOAG
- Share
- 1.9%
- Value
- $132m
- Shares
- 3,602,093
New
- AtaiBeckleyATAI
- Share
- 1.1%
- Value
- $76m
- Shares
- 14,417,442
+20%
- Generate BiomedicinesGENB
- Share
- 0.3%
- Value
- $23m
- Shares
- 1,333,815
New
- Kailera TherapeuticsKLRA
- Share
- 0.2%
- Value
- $15m
- Shares
- 700,000
New
- KardiganKARD
- Share
- 0.2%
- Value
- $14m
- Shares
- 600,000
New
- Immunocore HldgsIMCR
- Share
- 0.1%
- Value
- $10m
- Shares
- 311,218
-84%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Guardant HealthGH | 7.5% | $509m | 3,393,312 | Held |
| ImmunovantIMVT | 5.3% | $360m | 9,341,151 | -19% |
| Structure TherapeuticsGPCR | 3.7% | $254m | 4,740,072 | +11% |
| VaxcytePCVX | 3.7% | $250m | 4,300,000 | Held |
| Alnylam PharmaceuticalsALNY | 3.7% | $248m | 825,000 | New |
| VeradermicsMANE | 3.6% | $246m | 2,000,000 | +300% |
| Tarsus PharmaceuticalsTARS | 3.4% | $231m | 3,666,768 | Held |
| Nuvalent | 3.2% | $220m | 1,783,322 | +30% |
| Alkermes plc.ALKS | 3.1% | $210m | 4,000,000 | +11% |
| Ocular TherapeutixOCUL | 2.8% | $193m | 19,686,282 | Held |
| Biomarin PharmaceuticalBMRN | 2.8% | $189m | 3,307,481 | +188% |
| Nurix TherapeuticsNRIX | 2.8% | $188m | 7,736,455 | +22% |
| Oruka TherapeuticsORKA | 2.7% | $183m | 1,926,000 | -5% |
| AlumisALMS | 2.6% | $179m | 6,348,558 | -6% |
| Ionis PharmaceuticalsIONS | 2.6% | $174m | 2,200,000 | +13% |
| COMPASS PathwaysCMPS | 2.5% | $172m | 12,161,496 | Held |
| Vera TherapeuticsVERA | 2.5% | $172m | 4,000,000 | -3% |
| Axsome TherapeuticsAXSM | 2.5% | $171m | 700,000 | -36% |
| Genmab A/SGMAB | 2.3% | $155m | 5,650,000 | +54% |
| MoonLake ImmunotherapeuticsMLTX | 2.0% | $136m | 6,999,025 | +9% |
| Hemab Therapeutics HoldingsCOAG | 1.9% | $132m | 3,602,093 | New |
| Tango TherapeuticsTNGX | 1.9% | $131m | 4,200,000 | +53% |
| Definium TherapeuticsDFTX | 1.9% | $129m | 2,750,000 | -8% |
| GrailGRAL | 1.8% | $125m | 1,834,944 | +7% |
| Bicara TherapeuticsBCAX | 1.8% | $122m | 4,100,000 | Held |
| Maze TherapeuticsMAZE | 1.6% | $111m | 3,732,569 | +7% |
| Celldex TherapeuticsCLDX | 1.6% | $109m | 2,939,151 | +129% |
| LB PharmaceuticalsLBRX | 1.6% | $109m | 3,352,804 | Held |
| MBX BiosciencesMBX | 1.4% | $96m | 1,732,569 | -37% |
| GH ResearchGHRS | 1.3% | $90m | 3,333,334 | New |
| Cogent BiosciencesCOGT | 1.1% | $77m | 2,000,000 | +100% |
| AtaiBeckleyATAI | 1.1% | $76m | 14,417,442 | +20% |
| United TherapeuticsUTHR | 1.0% | $67m | 123,616 | New |
| Avalo TherapeuticsAVTX | 1.0% | $67m | 3,610,000 | New |
| Viridian TherapeuticsVRDN | 1.0% | $66m | 3,592,740 | +158% |
| CytokineticsCYTK | 0.9% | $60m | 700,000 | -49% |
| AltimmuneALT | 0.9% | $59m | 19,250,000 | New |
| PersonalisPSNL | 0.8% | $54m | 4,000,000 | +33% |
| Aclaris TherapeuticsACRS | 0.7% | $49m | 9,345,000 | Held |
| CorMedixCRMD | 0.7% | $49m | 6,274,076 | Held |
| GeneDx HoldingsWGS | 0.7% | $48m | 700,000 | New |
| HarrowHROW | 0.6% | $41m | 969,000 | New |
| Corvus PharmaceuticalsCRVS | 0.5% | $37m | 2,491,939 | Held |
| Solid BiosciencesSLDB | 0.5% | $36m | 3,565,062 | Held |
| Beam TherapeuticsBEAM | 0.5% | $34m | 1,000,000 | +22% |
| Dyne TherapeuticsDYN | 0.5% | $33m | 1,500,000 | -25% |
| Immix BiopharmaIMMX | 0.4% | $29m | 2,775,000 | New |
| X4 PharmaceuticalsXFOR | 0.4% | $27m | 5,878,757 | -7% |
| Shattuck LabsSTTK | 0.4% | $26m | 3,706,734 | New |
| MannkindMNKD | 0.4% | $26m | 6,000,000 | New |
| Century TherapeuticsIPSC | 0.3% | $23m | 9,462,645 | Held |
| Generate BiomedicinesGENB | 0.3% | $23m | 1,333,815 | New |
| VerastemVSTM | 0.3% | $22m | 5,740,850 | Held |
| Kura OncologyKURA | 0.3% | $22m | 1,978,565 | -25% |
| Enanta PharmaceuticalsENTA | 0.3% | $21m | 1,444,167 | -26% |
| Nektar TherapeuticsNKTR | 0.3% | $21m | 300,000 | New |
| Olema PharmaceuticalsOLMA | 0.3% | $19m | 1,500,000 | New |
| Kailera TherapeuticsKLRA | 0.2% | $15m | 700,000 | New |
| KardiganKARD | 0.2% | $14m | 600,000 | New |
| Enliven TherapeuticsELVN | 0.2% | $11m | 225,000 | New |
| ProMIS NeurosciencesPMN | 0.2% | $11m | 835,655 | Held |
| Immunocore HldgsIMCR | 0.1% | $10m | 311,218 | -84% |
| XencorXNCR | 0.1% | $10m | 593,551 | New |
| Context TherapeuticsCNTX | <0.1% | $4m | 7,419,355 | Held |
| InventivaIVA | <0.1% | $3m | 800,000 | -35% |
| Aligos TherapeuticsALGS | <0.1% | $3m | 444,110 | Held |
Options (1)
- Genmab A/SGMAB
- Type
- Call
- Value
- $82m
- Contracts
- 3,000,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| Genmab A/SGMAB | Call | $82m | 3,000,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 118.2% since 30 June 2025.
Where the money is
Health care90.6%
Other9.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.